CJC‑1295/Ipamorelin 5 mg / 5 mg is a premium research peptide blend designed for laboratory and preclinical studies focused on growth hormone (GH) stimulation, metabolic regulation, and tissue repair pathways. This dual-peptide formulation combines:

• CJC‑1295 (No DAC): A synthetic GHRH analog that stimulates GH release from the pituitary gland, supporting endocrine and metabolic research.

• Ipamorelin: A selective GH secretagogue peptide that promotes growth hormone secretion with minimal effects on cortisol and prolactin, allowing focused metabolic and tissue-repair studies.

The combination of these peptides is widely used in research to explore synergistic effects on GH pulses, cellular regeneration, metabolic pathways, and overall endocrine modulation. The short-acting CJC‑1295 (No DAC) complements Ipamorelin to produce consistent and reproducible GH stimulation, making it ideal for controlled in‑vitro assays and preclinical studies.

Key Research Benefits:

• Enhanced GH release: Dual-action formulation maximizes growth hormone secretion in experimental models.

• Metabolic and recovery research: Useful for studying fat metabolism, tissue repair, and energy regulation.

• Reproducible outcomes: High-purity peptides with validated analytical documentation ensure consistency.

• Controlled pulsatile stimulation: Short-acting formulation supports precise timing in research protocols.

• Versatile application: Suitable for preclinical, in‑vitro, and endocrine research studies.

Applications:

• Endocrine and growth hormone signaling studies

• Metabolic regulation and energy balance research

• Tissue repair and regenerative biology models

• Preclinical research on GH-related pathways

For research use only. Not intended for human or veterinary consumption.